Design and Recruitment for the GAP Trial, Investigating the Preventive Effect on Asthma Development of an SQ-Standardized Grass Allergy Immunotherapy Tablet in Children with Grass Pollen–Induced Allergic Rhinoconjunctivitis

Valovirta, Erkka; Berstad, A; Blic, J. de; Bufe, Albrecht; Eng, P. A.; Halken, Susanne; Ojeda, Pedro; Roberts, Graham; Tommerup, Lene; Varga, Eva‐Maria; Winnergård, Inger

doi:10.1016/j.clinthera.2011.09.013

Cited by 70 publications

(66 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As the quality of pediatric evidence in this area is not optimal, there is a need for well-designed, double-blind, placebo-controlled studies to assess the longterm immunotherapy effects in childhood [88]. The ongoing GAP (Grazax Asthma Prevention) trial represents the first double-blind, placebo-controlled randomized study aiming to assess the preventive effect of SIT on asthma development [89]. Last but not least, it must be kept in mind that the mechanisms leading to the disease-modifying effect, as well as the characteristics of patients particularly responsive to treatment, remain unclear.…”

Section: Allergen-specific Immunotherapymentioning

confidence: 99%

Pediatric Allergic Rhinitis and Asthma: Can the March be Halted?

et al. 2013

View full text Add to dashboard Cite

The strong epidemiologic and pathophysiologic link between allergic rhinitis (AR) and asthma has led to the concept of 'united airways disease' or 'respiratory allergy', implying that allergy, in its widest sense, underlies this clinical syndrome. Progression from AR to asthma is frequent and part of the 'atopic march'. Since pediatric immune responses are more adaptable and therefore may be more amenable to treatment, interventions at early childhood are characterized by a higher chance to affect the natural history of respiratory allergy. Although current treatments are quite effective in alleviating respiratory allergy symptoms, it has proven much more difficult to confirm any influence on the progression of the disease. Much more promising is the field of specific allergen immunotherapy, where current evidence, although not yet of ideal robustness, points towards a disease-modifying effect. In addition, newer or emerging, possibly more effective or more targeted interventions are promising in the preventive sense.

show abstract

Section: Allergen-specific Immunotherapymentioning

confidence: 99%

Pediatric Allergic Rhinitis and Asthma: Can the March be Halted?

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Both continuous and coseasonal protocols have been described, both seem to be effective although the latter may take longer to impact on the symptoms (135). There are also some nonblinded data to suggest that SLIT may prevent the development of asthma (136); these studies are now being repeated with a SLIT product using a placebo-controlled design (137). Two commercial grass products have received European market authorization for patients at least 5 years of age (138,139).…”

Section: Sublingual Immunotherapy (Slit)mentioning

confidence: 99%

Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology

Roberts

Xatzipsalti

Borrego

et al. 2013

Allergy

317

248

View full text Add to dashboard Cite

Rhinitis is a common problem in childhood and adolescence and impacts negatively on physical, social and psychological well-being. This position paper, prepared by the European Academy of Allergy and Clinical Immunology Taskforce on Rhinitis in Children, aims to provide evidence-based recommendations for the diagnosis and therapy of paediatric rhinitis. Rhinitis is characterized by at least two nasal symptoms: rhinorrhoea, blockage, sneezing or itching.

show abstract

“…Children and adolescents One low risk of bias pediatric study 110,111 Effective up to 2 y after cessation in adults. 108,109 One pediatric study was designed to look at prevention of asthma.…”

Section: Adultsmentioning

confidence: 99%

EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis

Roberts

Pfaar

Akdiş

et al. 2017

Allergy

593

705

View full text Add to dashboard Cite

drawn on data from a systematic review of the literature, more recent published studies and multistakeholder expert clinical opinion. This Guideline is aimed at healthcare professionals who are encouraged to take the recommendations into account in the context of delivering clinical care. This Guideline is not a substitute for professional clinical judgment, which professionals need to exercise in the context of delivering personalised healthcare. AbstractAllergic rhinoconjunctivitis (AR) is an allergic disorder of the nose and eyes affecting about a fifth of the general population. Symptoms of AR can be controlled with allergen avoidance measures and pharmacotherapy. However, many patients continue to have ongoing symptoms and an impaired quality of life; pharmacotherapy may also induce some side-effects. Allergen immunotherapy (AIT) represents the only currently available treatment that targets the underlying pathophysiology, and it may have a disease-modifying effect. Either the subcutaneous (SCIT) or sublingual (SLIT) routes may be used. This Guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (EAACI) Taskforce on AIT for AR and is part of the EAACI presidential project "EAACI Guidelines on Allergen Immunotherapy." It aims to provide evidence-based clinical recommendations and has been informed by a formal systematic review and meta-analysis. Its generation has followed the Appraisal of Guidelines for Research and Evaluation (AGREE II) approach.The process included involvement of the full range of stakeholders. In general, broad evidence for the clinical efficacy of AIT for AR exists but a product-specific evaluation of evidence is recommended. In general, SCIT and SLIT are recommended for both seasonal and perennial AR for its short-term benefit. The strongest evidence for long-term benefit is documented for grass AIT (especially for the grass 766 | ROBERTS, PFAAR ET AL. tablets) where long-term benefit is seen. To achieve long-term efficacy, it is recommended that a minimum of 3 years of therapy is used. Many gaps in the evidence base exist, particularly around long-term benefit and use in children. | ME TH ODOLOGYThis Guideline was produced using the Appraisal of Guidelines forResearch & Evaluation (AGREE II) approach, 17,18 a structured approach to guideline production (see Table S1). This is designed to ensure appropriate representation of the full range of stakeholders, a careful search for and critical appraisal of the relevant literature, a systematic approach to the formulation and presentation of recommendations and steps to ensure that the risk of bias is minimized at each step of the process. The process started on April 2015 beginning with detailed face-to-face discussions agreeing on the process and the key clinical areas to address, followed by face-to-face meetings, and regular web conferences in which professional and lay representatives participated. | Clarifying the scope and purpose of the guidelinesThe scope of this EAACI Guideline is multifaceted...

show abstract

Design and Recruitment for the GAP Trial, Investigating the Preventive Effect on Asthma Development of an SQ-Standardized Grass Allergy Immunotherapy Tablet in Children with Grass Pollen–Induced Allergic Rhinoconjunctivitis

Cited by 70 publications

References 32 publications

Pediatric Allergic Rhinitis and Asthma: Can the March be Halted?

Pediatric Allergic Rhinitis and Asthma: Can the March be Halted?

Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology

EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis

Contact Info

Product

Resources

About